The RTK MET and its ligand, hepatocyte growth factor (HGF), can activate a number of pathways, including the RAS-BRAF-ERK cascade, the PI3K-AKT axis, SRC, and STAT signaling [97]; these signaling networks collectively influence multiple key processes in cancer such as proliferation, apoptosis, invasion, and angiogenesis [98, 99]. This evidence concerns the gene MET and cancer.